Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Oculis Holding AG

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

OCULIS ACCELERATES ITS PORTFOLIO DEVELOPMENT WITH PRIVOSEGTOR MOVING INTO THE PIONEER PIVOTAL PROGRAM IN ACUTE OPTIC NEURITIS (AON) AND NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION) FOLLOWING POSITIVE FDA MEETING OCS-01 DIAMOND PHASE 3 TRIALS IN DIABETIC MACULAR EDEMA (DME) REMAIN ON TRACK FOR TOPLINE RESULTS EXPECTED IN Q2 2026 LICAMINLIMAB PREDICT-1 REGISTRATIONAL TRIAL, THE FIRST GENOTYPE-BASED TRIAL TO DRIVE PRECISION MEDICINE IN DRY EYE DISEASE (DED), EXPECTED TO START IN Q4 2025 CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $182.2 MILLION AS OF SEPTEMBER 30, 2025 PLUS RECENT $110 MILLION FINANCING, EXTEND CASH RUNWAY INTO 2029 ZUG, SWITZERLAND, NOV. 10, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (OCULIS), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON BREAKTHROUGH INNOVATIONS TO ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS IN OPHTHALMOLOGY AND NEURO-OPHTHALMOLOGY, TODAY ANNOUNCED RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED AN OVERVIEW OF THE COMPANY'S PROGRESS. RIAD SHERIF, M.D.

OCULIS REPORTS Q3 2025 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

ZUG, SWITZERLAND, NOV. 05, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (OCULIS), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON BREAKTHROUGH INNOVATIONS TO ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS IN NEURO-OPHTHALMOLOGY AND OPHTHALMOLOGY, ANNOUNCED TODAY THAT OCULIS' MANAGEMENT WILL PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN NOVEMBER. OCULIS IS PLEASED TO PRESENT UPDATES OF ITS INNOVATIVE, HIGHLY DIFFERENTIATED, LATE-STAGE PORTFOLIO AS IT ENTERS A PIVOTAL PHASEIN ITS TRANSFORMATIONINTO A LEADER IN NEURO-OPHTHALMOLOGY AND OPHTHALMOLOGY.

OCULIS TO PARTICIPATE IN UPCOMING NOVEMBER INVESTOR CONFERENCES

ZUG, SWITZERLAND, OCT. 30, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS; XICE: OCS) (OCULIS OR THE COMPANY), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON BREAKTHROUGH INNOVATIONS TO ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS IN OPHTHALMOLOGY AND NEURO-OPHTHALMOLOGY, TODAY ANNOUNCED THE PRICING OF OFFERINGS OF AN AGGREGATE OF 5,432,098 OF ITS ORDINARY SHARES, CHF 0.01 NOMINAL VALUE PER SHARE, AT A PRICE OF $20.25 PER SHARE FOR TOTAL GROSS PROCEEDS OF $110 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES. IN CONNECTION WITH THE UNDERWRITTEN OFFERING, THE COMPANY HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 703,703 ORDINARY SHARES AT A PRICE OF $20.25 PER SHARE.

OCULIS ANNOUNCES OVERSUBSCRIBED $110 MILLION FINANCING TO ACCELERATE PRIVOSEGTOR DEVELOPMENT

ZUG, SWITZERLAND, OCT. 14, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED TWO NOTIFICATIONS RELATE TO THE EXERCISE OF VESTED STOCK OPTIONS TO PURCHASE ORDINARY SHARES PREVIOUSLY GRANTED TO A DIRECTOR OF THE COMPANY, AND THE SUBSEQUENT SALE OF THOSE ORDINARY SHARES. THESE TRANSACTIONS WERE ENTERED INTO PURSUANT TO A 10B5-1 TRADING PLAN, IN ACCORDANCE WITH RULE 10B5-1(C)(1) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

ZUG, SWITZERLAND, OCT. 14, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (OCULIS), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIONS FOR OPHTHALMIC AND NEURO-OPHTHALMIC DISEASES WITH SIGNIFICANT UNMET MEDICAL NEEDS,TODAY ANNOUNCED THAT OCULIS' INNOVATIVE LATE-STAGE PIPELINE WILL BE HIGHLIGHTED AT EYECELERATOR AND AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) ANNUAL MEETING.

OCULIS TO SPOTLIGHT TRANSFORMATIVE LATE-STAGE PIPELINE AT EYECELERATOR AND AAO 2025

ZUG, SWITZERLAND, OCT. 08, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO THE VESTING AND SETTLEMENT OF RSUS PREVIOUSLY GRANTED TO A DIRECTOR OF THE COMPANY.

SUCCESSFUL MEETING WITH FDA ENABLES ADVANCEMENT INTO PIVOTAL DEVELOPMENT WITH PRIVOSEGTOR IN ACUTE OPTIC NEURITIS (AON) AND NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION)

OCULIS ACCELERATES PRIVOSEGTOR INTO REGISTRATIONAL TRIALS IN ACUTE OPTIC NEURITIS, PIONEERING THE PATH FOR A POTENTIAL FIRST-IN-CLASS NEUROPROTECTIVE THERAPY

ZUG, SWITZERLAND, SEPT. 26, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO TRADES ENTERED INTO BY A PDMR OF THE COMPANY PURSUANT TO A 10B5-1 TRADING PLAN, IN ACCORDANCE WITH RULE 10B5-1(C)(1) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

OCULIS PUBLISHES NOTIFICATION OF TRANSACTIONS BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

NEXE EXPANDS WITH 4 NEW COMPOSTABLE COFFEE POD SKUS, INCLUDING PUMPKIN, VIA MAJOR OCS PARTNERDRIVING SUSTAINABLE GROWTH AND WIDER MARKET ACCESS. 

NEXE INNOVATIONS EXPANDS PRODUCT PORTFOLIO WITH SEVERAL NEW SKUS IN COLLABORATION WITH NORTH AMERICAN OCS PARTNER

ZUG, SWITZERLAND, SEPT. 22, 2025 (GLOBE NEWSWIRE) -- PRIVOSEGTOR ACUITY TRIAL SHOWED IMPROVED LCVA AND PRESERVATION OF GANGLION CELLS IN ACUTE OPTIC NEURITIS. RESULTS FROM A MULTICENTER RANDOMIZED PLACEBO-CONTROLLED DOUBLE-MASKED TRIAL

Oculis Holding AG

OCS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Oculis Holding AG

OCS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

OCS